1.
Chinese Journal of Urology
;
(12): 548-550, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-994082
RESUMO
At present, systemic therapy is the main treatment option for metastatic renal cell carcinoma. However, active surveillance may be an alternative for patients with poor physical status or slow disease progression. Active surveillance can appropriately delay the timing of systematic treatment for some patients with metastatic renal cell carcinoma without affecting their prognosis. We have combined the latest researches to clarify the clinical significance, applicable population, disadvantages, scheme and prognosis of active surveillance in metastatic renal cell carcinoma in recent years in detail.